Recent research has uncovered that individuals with specific genetic variations linked to appetite and digestion are more likely to experience significant weight loss when using medications such as Wegovy and Mounjaro. This groundbreaking study, published in the journal *Nature*, highlights the complex interplay of genetics and other factors that influence the efficacy and side effects of these popular obesity treatments.
Genetic Variants and Weight Loss
The study examined data from approximately 15,000 participants who had undergone genetic testing through the company 23andMe. Researchers identified distinct genetic variants associated with weight loss, suggesting that these genetic markers could explain the variability in outcomes among users of weight-loss drugs. For instance, individuals carrying a specific variant tended to lose an average of 0.76 kg (1.6 lbs) more than those without it. Remarkably, those with two copies of this gene could double their weight loss.
Professor Ruth Loos from the University of Copenhagen, who contributed to the research, noted that 64% of individuals with European ancestry possess at least one copy of this variant, while only 7% of African Americans do. This disparity raises questions about how genetic predisposition interacts with weight-loss strategies, pointing to a potential need for personalised approaches in treatment.
Side Effects and Their Genetic Links
The research also discovered that certain genetic variations could predispose individuals to experience more severe side effects when using tirzepatide, one of the drugs in question. Approximately 1% of users may face extreme nausea, with symptoms nearly 15 times more severe than typical experiences. This connection between genetics and adverse reactions underscores the importance of understanding individual responses to medication.
While genetic factors play a role, experts caution that they are only one piece of a much larger puzzle. The effectiveness of weight-loss drugs is also influenced by behaviours, demographics, and other clinical factors.
Broader Influences on Weight-Loss Outcomes
Alongside genetic predisposition, various demographic factors contribute to differences in weight loss among users. Research indicates that women are more than twice as likely to lose at least 15% of their body weight when using Mounjaro compared to men. Age, ethnicity, and the specific medication used also appear to significantly affect weight-loss outcomes. Younger individuals, as well as those of white or Asian descent, tend to achieve greater weight loss, although the underlying reasons for these trends are not fully understood.
Experts like Dr Marie Spreckley from the University of Cambridge emphasise that behavioural factors, such as levels of physical activity and adherence to dietary recommendations, are critical in determining the success of weight-loss treatments. The degree of support provided to individuals during their treatment journey is equally essential.
The Future of Precision Medicine in Weight Loss
Looking ahead, the integration of genetic and other personal data could pave the way for a more tailored approach to weight-loss treatments, often referred to as “precision medicine.” Although this study presents intriguing insights, Professor Naveed Sattar from the University of Glasgow cautions that we are still far from implementing these findings into clinical practice. He highlights the need for further robust trials to establish a clearer understanding of the benefits and risks associated with these emerging therapies.
Why it Matters
Understanding the genetic factors that influence weight loss can significantly impact public health strategies aimed at tackling obesity. As the prevalence of obesity continues to rise, particularly in the UK where an estimated 1.6 million individuals have turned to weight-loss medications recently, these findings could inform more effective treatment protocols. Personalising interventions based on genetic and demographic profiles not only has the potential to enhance individual outcomes but also to reduce the burden of obesity-related health issues on society. The continued exploration of these dimensions is vital for shaping future healthcare approaches and ensuring that treatments are both effective and safe for diverse populations.
